Gillie Daniel J, Novick Steven J, Donovan Brian T, Payne Lisa A, Townsend Claire
Biological Reagents and Assay Development, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA.
J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):33-44. doi: 10.1016/j.vascn.2012.10.002. Epub 2012 Oct 26.
Drug-induced prolongation of the QT interval via block of the hERG potassium channel is a major cause of attrition in drug development. The advent of automated electrophysiology systems has enabled the detection of hERG block earlier in drug discovery. In this study, we have evaluated the suitability of a second generation automated patch clamp instrument, the IonWorks Barracuda, for the characterization of hERG biophysics and pharmacology.
All experiments were conducted with cells stably expressing hERG. Recordings were made in perforated patch mode either on a conventional patch clamp setup or on the IonWorks Barracuda. On the latter, all recordings were population recordings in 384-well patch plates.
HERG channels activated with a V(1/2)=-3.2±1.6mV (n=178) on the IonWorks Barracuda versus -11.2±6.1mV (n=9) by manual patch clamp. On the IonWorks Barracuda, seal resistances and currents were stable (<30% change) with up to six cumulative drug additions and 1-min incubations per addition. Over 27 experiments, an average of 338 concentration-response curves were obtained per experiment (96% of the 352 test wells on each plate). HERG pharmacology was examined with a set of 353 compounds that included well-characterized hERG blockers. Astemizole, terfenadine and quinidine inhibited hERG currents with IC(50) values of 159nM, 224nM and 2μM, respectively (n=51, 10 and 18). This set of compounds was also tested on the PatchXpress automated electrophysiology system. We determined through statistical methods that the two automated systems provided equivalent results.
Evaluating drug effects on hERG channels is best performed by electrophysiological methods. HERG activation and pharmacology on the IonWorks Barracuda automated electrophysiology platform were in good agreement with published electrophysiology results. Therefore, the IonWorks Barracuda provides an efficient way to study hERG biophysics and pharmacology.
通过阻断人醚 - 去极化激活的钾通道(hERG)导致的药物诱导的QT间期延长是药物研发失败的主要原因。自动化电生理系统的出现使得在药物发现的早期就能检测到hERG阻断。在本研究中,我们评估了第二代自动化膜片钳仪器IonWorks Barracuda用于表征hERG生物物理学和药理学的适用性。
所有实验均使用稳定表达hERG的细胞进行。记录在穿孔膜片钳模式下进行,可在传统膜片钳装置或IonWorks Barracuda上进行。在后者上,所有记录均为384孔膜片板中的群体记录。
在IonWorks Barracuda上,hERG通道激活的半激活电压(V(1/2))为-3.2±1.6mV(n = 178),而手动膜片钳测得的为-11.2±6.1mV(n = 9)。在IonWorks Barracuda上,每次添加药物后进行1分钟孵育,累积添加多达六种药物时,封接电阻和电流保持稳定(变化<30%)。在27次实验中,每次实验平均获得338条浓度 - 反应曲线(占每块板上352个测试孔的96%)。使用一组353种化合物研究hERG药理学,其中包括特征明确的hERG阻断剂。阿司咪唑、特非那定和奎尼丁抑制hERG电流的半数抑制浓度(IC(50))值分别为159nM、224nM和2μM(n = 51、10和18)。这组化合物也在PatchXpress自动化电生理系统上进行了测试。我们通过统计方法确定这两种自动化系统提供了等效的结果。
评估药物对hERG通道的影响最好通过电生理方法进行。IonWorks Barracuda自动化电生理平台上的hERG激活和药理学与已发表的电生理结果高度一致。因此,IonWorks Barracuda为研究hERG生物物理学和药理学提供了一种有效的方法。